Literature DB >> 2455519

Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages.

J P Bökkerink1, M A Bakker, T W Hulscher, R A De Abreu, E D Schretlen.   

Abstract

Methotrexate (MTX) causes an inhibition of purine de novo synthesis (PDNS), resulting in increased intracellular availability of 5-phosphoribosyl-1-pyrophosphate (PRPP) in human malignant lymphoblasts with an active PDNS. Normal bone marrow cells and peripheral blood lymphocytes lack this capacity. The increased levels of PRPP can be used for enhanced incorporation of 6-mercaptopurine (6MP), indicating a potential time-, sequence- and dose-dependent synergism of both drugs. The effects of 0.02 microM and 0.2 microM MTX on the PDNS of MOLT-4 (T-), RAJI (B-) and KM-3 (non-B-non-T-) human malignant lymphoblasts were studied with respect to PRPP levels, aminoimidazolecarboxamide ribonucleosidemonophosphate (AICAR) levels and the incorporation of labeled glycine into purine metabolites. These results were correlated with the activity of the PDNS (labeled glycine incorporation) and the purine salvage pathway (labeled hypoxanthine incorporation) in untreated cells. Inhibition of PDNS by 0.02 microM MTX was complete in KM-3 cells with a moderately active PDNS and salvage pathway. RAJI cells, with a relatively low PDNS and high salvage pathway, demonstrated an incomplete, but increasing inhibition of PDNS, whereas inhibition of PDNS in MOLT-4 cells with both pathways active was minimal and recovered in time. Treatment with 0.2 microM MTX resulted in a complete inhibition of PDNS in all cell lines. After treatment with MTX an enhanced incorporation of labeled hypoxanthine and 6MP was noticed, confirming the potential rescue from MTX cytotoxicity by hypoxanthine and a potential synergism of MTX and 6MP on cytotoxicity. The enhanced incorporation of 6MP was more obvious in RAJI and KM-3 cells in comparison with MOLT-4 cells. These data demonstrate the important role of both the activities of the PDNS and the purine salvage pathway in malignant lymphoblasts of different subclasses with respect to the synergism of MTX and 6MP.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455519     DOI: 10.1016/0006-2952(88)90358-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Methotrexate promotes glucose uptake and lipid oxidation in skeletal muscle via AMPK activation.

Authors:  Sergej Pirkmajer; Sameer S Kulkarni; Robby Z Tom; Fiona A Ross; Simon A Hawley; D Grahame Hardie; Juleen R Zierath; Alexander V Chibalin
Journal:  Diabetes       Date:  2014-10-22       Impact factor: 9.461

2.  Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.

Authors:  Mette Levinsen; Susanne Rosthøj; Ulrikka Nygaard; Jesper Heldrup; Arja Harila-Saari; Olafur G Jonsson; Anne Grete Bechensteen; Jonas Abrahamsson; Birgitte Lausen; Thomas L Frandsen; Richard M Weinshilboum; Kjeld Schmiegelow
Journal:  Cancer Chemother Pharmacol       Date:  2014-10-28       Impact factor: 3.333

3.  Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.

Authors:  Torben S Mikkelsen; Alex Sparreboom; Cheng Cheng; Yinmei Zhou; James M Boyett; Susana C Raimondi; John C Panetta; W Paul Bowman; John T Sandlund; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

4.  Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.

Authors:  Gianluigi Zaza; Meyling Cheok; Wenjian Yang; John C Panetta; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  Blood       Date:  2005-05-19       Impact factor: 22.113

5.  Methotrexate and erythro-9-(2-hydroxynon-3-yl) adenine therapy for rat adjuvant arthritis and the effect of methotrexate on in vivo purine metabolism.

Authors:  Joseph E Baggott; Sarah L Morgan
Journal:  Eur J Pharm Sci       Date:  2007-03-01       Impact factor: 4.384

Review 6.  Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes.

Authors:  E Masson; W C Zamboni
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

7.  Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

Authors:  E Masson; M V Relling; T W Synold; Q Liu; J D Schuetz; J T Sandlund; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

Review 8.  Nucleoside salvage and resistance to antimetabolite anticancer agents.

Authors:  M Fox; J M Boyle; A R Kinsella
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

9.  A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.

Authors:  Shibani Nicum; Corran Roberts; Lucy Boyle; Sylwia Kopijasz; Charlie Gourley; Marcia Hall; Ana Montes; Christopher Poole; Linda Collins; Anna Schuh; Susan J Dutton
Journal:  BMC Cancer       Date:  2014-12-19       Impact factor: 4.430

Review 10.  Pharmacogenetic studies of thiopurine methyltransferase genotype-phenotype concordance and effect of methotrexate on thiopurine metabolism.

Authors:  Anna Zimdahl Kahlin; Sara Helander; Patricia Wennerstrand; Svante Vikingsson; Lars-Göran Mårtensson; Malin Lindqvist Appell
Journal:  Basic Clin Pharmacol Toxicol       Date:  2020-09-14       Impact factor: 4.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.